Revolutionary eazySNP Test Merges LAMP and CRISPR for Rapid Genetic Detection

A Breakthrough in Molecular Diagnostics: The Launch of eazySNP

MUNICH, Oct. 20, 2026 - AmplexDiagnostics and Scope Biosciences have unveiled a pioneering product in the field of molecular diagnostics. This innovation, named eazySNP, fuses two cutting-edge molecular technologies, LAMP (Loop-mediated Isothermal Amplification) and CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats). Together, these methods create a powerful tool for the rapid and precise detection of genetic variants.

The development of eazySNP is a result of a fruitful collaboration between AmplexDiagnostics and Scope Biosciences. This union of expertise has made waves in the domain of SNP (Single Nucleotide Polymorphism) diagnostics, signifying a notable evolution in pathogen detection techniques. The introduction of eazySNP, which has successfully earned the CE-IVD mark, highlights a significant step forward in diagnostics, as it is now recognized for clinical use in Europe.

Targeting Multidrug-Resistant Pathogens

The inaugural application of the eazySNP technology is focused on a crucial concern within the medical community: the Candida auris fungus, notorious for its multidrug-resistant properties. Specifically, the diagnostic test eazySNP C. auris FKS1 S639 showcases the ability to detect mutations in the FKS1 gene that are linked with resistance to echinocandins, which currently serve as first-line treatments against C. auris infections. This swift identification of resistance markers is invaluable for patient management and treatment strategies.

The eazySNP test operates directly from a yeast colony using the AmplexDiagnostics eazyMini platform, yielding results in a mere 45 minutes. This rapid turnaround forces a paradigm shift, offering a focused solution for the identification of this significant resistance marker, ultimately improving patient outcomes through timely interventions.

A New Era of Diagnostics

According to Bas van der Baan, CEO of Scope Biosciences, the launch marks a vital milestone in the company’s evolution. “Our CRISPR technology has transitioned from a versatile research platform to a regulated product addressing a pressing diagnostic need,” he affirmed. The collaboration with AmplexDiagnostics has enabled the transformation of single-nucleotide precision techniques into a practical assessment tool suitable for routine laboratory diagnostics.

This milestone does not only demonstrate the commitment of both companies to advance human molecular diagnostics but also signifies the possibilities for further developments in plant health innovations. Scope Biosciences intends to leverage this experience and continue expanding its offerings in both human and plant diagnostic sectors.

Conclusion

The introduction of the eazySNP technology not only sets a new benchmark in the diagnostic landscape but exemplifies the potential of interdisciplinary collaboration between technology and healthcare. With the merging of LAMP and CRISPR, eazySNP is poised to make significant impacts in clinical environments, particularly in relation to infectious diseases and resistance monitoring. As the future unfolds, the adaptability and speed of diagnostics will undoubtedly play a crucial role in combating emerging health threats. For more information, the companies welcome direct inquiries via their website or contact details provided.